









Markets
/
Stocks
/
nasdaq-zyme
/

Zymeworks Inc

ZYME

19.085USD

-0.035-0.18%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

1.34BMarket Cap

LossP/E TTM



Zymeworks Inc

19.085

-0.035-0.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Zymeworks Inc

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zymeworks Inc's Score

Industry at a Glance

Industry Ranking

1 / 407

Overall Ranking

26 / 4618

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.611

Target Price

+28.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Zymeworks Inc Highlights

StrengthsRisks

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.30M.

Undervalued

The company’s latest PE is -19.50, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 77.15M shares, increasing 1.35% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 71.98K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 9.36, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 48.73M, representing a year-over-year increase of 153.21%, while its net profit experienced a year-over-year increase of 106.15%.

Score

Industry at a Glance

Previous score

9.36

Change



Financials

8.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Zymeworks Inc's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 6.92, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -19.50, which is -127.00% below the recent high of 5.26 and -1.55% above the recent low of -19.80.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 1/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Zymeworks Inc is 24.00, with a high of 32.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.611

Target Price

+28.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Zymeworks Inc

ZYME

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 9.24, which is higher than the Biotechnology & Medical Research industry's average of 6.66. Sideways: Currently, the stock price is trading between the resistance level at 20.64 and the support level at 16.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.26

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.084

Buy

RSI(14)

67.151

Neutral

STOCH(KDJ)(9,3,3)

71.163

Neutral

ATR(14)

0.796

Low Volatility

CCI(14)

79.196

Neutral

Williams %R

33.026

Buy

TRIX(12,20)

0.546

Sell

StochRSI(14)

26.939

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

19.071

Buy

MA10

18.443

Buy

MA20

18.059

Buy

MA50

16.653

Buy

MA100

14.920

Buy

MA200

13.786

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 102.64%, representing a quarter-over-quarter decrease of 0.09%. The largest institutional shareholder is The Vanguard, holding a total of 2.46M shares, representing 3.27% of shares outstanding, with 9.24% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

EcoR1 Capital, LLC

22.97M

+28.44%

Rubric Capital Management LP

4.71M

+8.58%

BVF Partners L.P.

4.31M

Redmile Group, LLC

4.15M

-13.33%

Morgan Stanley & Co. LLC

3.62M

+9.60%

BlackRock Institutional Trust Company, N.A.

3.11M

-8.46%

The Vanguard Group, Inc.

Star Investors

2.46M

+39.45%

BNP Paribas Asset Management USA, Inc.

2.04M

-7.22%

Blackstone Alternative Asset Management, L.P.

1.66M

+19.83%

UBS Asset Management (Americas) LLC

1.46M

-9.14%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 6.48, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.